Perimenopause Fatigue That Is Not Iron and Not Thyroid: The Cardiac Workup Nobody Runs

Perimenopausal women with normal thyroid and normal iron studies frequently have cardiac causes of fatigue that no one evaluates. The three most common are HFpEF, coronary microvascular dysfunction, and autonomic dysregulation. All are female-predominant, all are tied to estrogen decline, and all are missed when the workup ends at TSH, ferritin, and a resting echocardiogram. HFpEF now accounts for at least half of all heart failure, and women dominate that phenotype.

The Workup That Stops Too Soon

Normal thyroid. Normal iron. Still exhausted at 2pm. Here is what the workup is missing.

A 49-year-old woman sat in my office last spring with a folder of normal results. TSH 2.1. Ferritin 68. Complete blood count clean. Her primary care physician had told her she was depressed and offered an SSRI. She had taken it for three months. The fatigue did not move. “I can’t function,” she told me. “My iron is fine. My thyroid is fine. I think something is wrong with my heart.”

She was right.

This is the most common diagnostic path for a woman between 40 and 55 with severe fatigue. The thyroid gets checked. The iron gets checked. Both come back normal. She is told to exercise more, sleep better, manage her stress. The cardiac diagnoses that actually explain exertional fatigue in this age group are never considered. The gap between a normal TSH and a cardiologist’s assessment is exactly where her diagnosis lives.

Women don’t die from what they have. Women die from what they hold. They hold a normal lab panel and a label that explains nothing. They hold “you’re just stressed” for two years while a stiffening heart goes unexamined.

Diagnose Before You Treat

Fatigue is not one condition. It is a symptom with at least three distinct origins in midlife women, and they require different tests and different treatments. Before anyone hands you an antidepressant or a sleep hygiene pamphlet, the differential needs to be worked, not assumed.

Hormonal fatigue comes from the estrogen fluctuation of perimenopause itself. It tracks with cycle disruption, hot flashes, and sleep fragmentation. It tends to be worse in the days before a period and improves with hormonal stabilization.

Metabolic fatigue comes from thyroid disease, iron deficiency, and increasingly, insulin resistance. This is the category your standard workup actually screens. When TSH and ferritin are normal, this box is mostly checked, except for one piece almost no one orders: a fasting insulin or HOMA-IR. Insulin resistance produces profound afternoon fatigue and is rampant in midlife women with central weight gain.

Cardiac fatigue comes from three conditions that no standard panel touches. HFpEF. Coronary microvascular dysfunction. Autonomic dysregulation. These are the diagnoses that get lost.

The error in primary care is not negligence. It is sequence. Depression gets named first because it requires no further testing. But depression is a diagnosis of exclusion. You earn it by clearing the cardiac and metabolic differential, not by defaulting to it when the first two labs are normal.

The Three Cardiac Diagnoses Nobody Runs

HFpEF: The Stiff Heart That Looks Normal

Heart failure with preserved ejection fraction is the diagnosis most likely to be hiding behind “normal thyroid, normal iron, still exhausted.” HFpEF now represents at least half of all heart failure cases, and women are over-represented, particularly older and postmenopausal women (Sabbatini 2022). (Honesty: 5/Solid)

The pump works fine. The ejection fraction is 55 or 60 percent, completely normal. The problem is not contraction. It is relaxation. The heart muscle stiffens, fills poorly, and pressures rise inside the chambers when the body demands more output. At rest, everything looks acceptable. Under exertion, filling pressures climb sharply and the patient hits a wall.

The presenting complaint is not chest-clutching drama. The most common symptoms in HFpEF cohorts are exertional fatigue and reduced exercise tolerance (Sharma 2024). (Honesty: 5/Solid) The woman who could carry groceries up two flights last year now stops on the landing. She is not deconditioned. Her heart cannot raise its filling pressure without cost.

Why does menopause set this up? Estrogen decline drives a cascade. Visceral and epicardial fat accumulate after the final menstrual period, and that fat is metabolically active, secreting inflammatory cytokines that promote myocardial fibrosis and stiffening (Sharma 2024). (Honesty: 4/Promising) Estrogen normally suppresses the renin-angiotensin-aldosterone system. Its loss lifts that suppression, raising angiotensin II and aldosterone, which drive hypertension and interstitial fibrosis (Sabbatini 2022). (Honesty: 4/Promising) Hypertension is present in roughly 80 to 90 percent of HFpEF patients. The stiff heart and the high pressure feed each other.

The diagnostic trap is the resting echocardiogram. HFpEF frequently shows abnormal hemodynamics only during exercise, not at rest (Borlaug 2015). (Honesty: 5/Solid) A normal resting echo does not exclude it. This is why so many women are reassured and sent home with their fatigue intact. The full evaluation of HFpEF symptoms in women requires exertional testing, not a single resting image.

Coronary Microvascular Dysfunction: Clean Arteries, Starved Muscle

The second diagnosis is coronary microvascular dysfunction. The large coronary arteries are clean. An angiogram would look perfect. But the small vessels, the microvasculature that actually delivers blood into the muscle, cannot dilate properly to meet demand.

Among women with chest pain and no obstructive coronary disease on angiography, up to 50 to 65 percent have evidence of microvascular dysfunction or vasospasm on advanced testing. This is not benign. Women with this pattern carry a two- to four-fold higher risk of major adverse cardiac events over the following five to ten years compared to asymptomatic women, even with clean angiograms.

Estrogen is a vasodilator and an anti-inflammatory. Its withdrawal reduces nitric oxide availability, impairs the endothelium, and contributes to capillary rarefaction. Women have smaller coronary arteries to begin with, and menopause strips away the protective signaling that kept the microvasculature responsive. The result is a heart that cannot augment its own blood flow under load.

Clinically this looks like hitting a wall climbing stairs, sometimes with a diffuse pressure that is not the classic crushing chest pain men report. The standard treadmill stress test is often falsely reassuring, because it is built to detect blockages in the large arteries, not failure in the small ones. The proper evaluation of microvascular disease in women requires coronary flow reserve measurement, PET, or stress cardiac MRI, tests that are rarely ordered for a woman whose complaint is filed under fatigue.

Autonomic Dysregulation: The Nervous System Loses Its Tune

The third diagnosis is autonomic dysregulation. The autonomic nervous system controls heart rate, blood pressure, and the moment-to-moment adjustments your circulation makes when you stand, exert, or sleep. Estrogen modulates this system directly.

As estrogen declines, sympathetic tone rises and vagal tone falls. Resting heart rate goes up. Heart rate variability, a marker of autonomic balance, deteriorates. Baroreflex sensitivity, the reflex that stabilizes blood pressure when you change position, weakens. Nocturnal sympathetic surges fragment sleep, often layered on top of vasomotor symptoms.

A subset of midlife women develop a frankly orthostatic phenotype, sometimes meeting criteria for POTS, postural orthostatic tachycardia syndrome. They stand and their heart races, they feel lightheaded, and they are flattened by fatigue. POTS is strongly female-predominant and clusters in this exact age window. It is almost universally attributed to anxiety in primary care.

These autonomic problems mimic HFpEF and microvascular disease symptomatically. Fatigue, exercise intolerance, palpitations. But a resting echo and an office ECG are completely normal, which is exactly why the woman gets told it is in her head.

The OES Triad: How I Sort Cardiac From Non-Cardiac Fatigue

In practice I use a three-feature screen to decide whether a woman’s fatigue earns a cardiac workup after normal standard labs. I call it the OES Triad. When any one of these is present, the cardiac differential is open and a normal TSH does not close it.

O is for Onset with exertion. Hormonal and depressive fatigue tend to be constant or worse in the morning. Cardiac fatigue is exertional. It appears when the heart is asked to do work and recedes with rest. The question I ask is simple: does the fatigue arrive when you climb stairs or carry weight, and ease when you sit down? A yes points toward the heart.

E is for Erosion of capacity. This is a measurable decline in what you can do, tracked over months. Last year two flights, this year one. Last year a full grocery run, now a divided one. Hormonal fatigue makes you tired. Cardiac fatigue makes you smaller. When a woman can name the specific task that used to be easy and now is not, that is erosion, and erosion is a cardiac flag.

S is for Symptom companions. Breathlessness with exertion that resolves with rest. Chest pressure, even diffuse and non-classic. Palpitations or a racing heart on standing. Ankle swelling by evening. Any of these alongside fatigue moves the probability sharply toward HFpEF, microvascular disease, or autonomic dysregulation.

The OES Triad does not diagnose anything. It decides who needs to be tested rather than reassured. A woman with all three features and a normal lab panel has been failed if no one has measured her NT-proBNP or imaged her heart under load.

The Workup You Should Actually Request

When the OES Triad is positive and standard labs are normal, here is the sequence that closes the gap.

NT-proBNP. This is the highest-yield first move. It rises when cardiac filling pressures are elevated, the signature of HFpEF. An elevated value mandates imaging. But the critical caveat for midlife women: NT-proBNP runs falsely low in the setting of obesity and central adiposity. A normal value in an overweight woman does not rule out HFpEF (Borlaug 2015). (Honesty: 5/Solid) If you carry abdominal weight and your NT-proBNP is normal, the heart is not cleared. The test was blunted.

Exercise or diastolic stress echocardiogram. This is the test that catches what the resting echo misses. By measuring filling pressures during exertion, it reveals the HFpEF that hides at rest. If your fatigue is exertional and your resting echo was normal, this is the next correct step.

Coronary flow reserve, PET, or stress cardiac MRI. When chest pressure accompanies the fatigue and large-artery disease has been excluded, these tests evaluate the microvasculature directly. They are the only way to diagnose microvascular dysfunction. A normal angiogram does not exclude ischemia in women.

Tilt-table testing or active stand with heart rate monitoring. When the fatigue is orthostatic, when standing makes the heart race, this evaluation identifies POTS and autonomic dysregulation.

Fasting insulin and HOMA-IR. Not strictly cardiac, but the metabolic piece that standard panels skip. Insulin resistance produces severe afternoon fatigue and accelerates the inflammatory drive toward HFpEF. It belongs in the workup.

Why Depression Is the Last Box, Not the First

A clinical inversion needs to be stated plainly. Depression is a real condition, and fatigue is one of its symptoms. But in a 49-year-old woman with exertional fatigue and a measurable drop in exercise tolerance, depression cannot be the opening assumption. It is the diagnosis you reach after the cardiac and metabolic differential is clear, not the one you reach because the first two labs were normal and the visit was running long.

When a woman says her fatigue is so severe she cannot function, that her iron and thyroid are fine, and that she thinks something is wrong with her heart, the correct response is to test the heart. Her self-assessment is data. Women under-report and under-dramatize cardiac symptoms. A woman who insists something is wrong with her heart is more often right than the chart gives her credit for.

The cost of defaulting to depression is not just a wasted prescription. It is two years of an undiagnosed stiffening heart, untreated hypertension, and a missed window to intervene while the disease is still modifiable. HFpEF caught early, with blood pressure controlled, weight addressed, and the metabolic drivers treated, has a very different trajectory than HFpEF discovered after the first hospitalization for breathlessness.

What Changes When You Get the Right Diagnosis

The treatments diverge completely by cause, which is the whole point of working the differential.

HFpEF responds to aggressive blood pressure control, weight reduction, treatment of insulin resistance, and increasingly to SGLT2 inhibitors, which now carry evidence in this population. Hormonal fatigue may respond to hormone therapy when started appropriately. Microvascular dysfunction is treated with specific anti-anginal and vasodilatory strategies. Autonomic dysregulation and POTS respond to volume expansion, targeted exercise protocols, and sometimes medication that an SSRI for “depression” would never touch.

Give the wrong woman an antidepressant and you have treated nothing. Give the right woman a diastolic stress echo and you have found the disease. The difference is whether anyone ran the workup.

This is the central failure of midlife women’s cardiac care. The conditions that explain their fatigue are female-predominant, menopause-linked, and absent from the standard panel. The tests exist. The diagnoses are established in current guidelines, which now formally recognize HFpEF as true heart failure and microvascular disease as a legitimate, prognostically significant condition. What is missing is the decision to look.

If you are reading this with a folder of normal results and a body that is still failing you at 2pm, the problem is not that nothing is wrong. The problem is that no one finished the workup.

Your Next Step

Take the perimenopause cardiac risk assessment. It runs the OES Triad against your specific symptoms and tells you, in plain terms, whether your fatigue carries cardiac features that warrant NT-proBNP and an exercise echocardiogram. If your assessment flags cardiac risk, bring the result to your physician and request the specific panel: NT-proBNP, fasting insulin, and a diastolic stress echocardiogram. Do not accept a third reassurance that your normal thyroid and normal iron explain why you cannot function. They do not. The diagnosis lives in the test nobody ran.

For deeper reading on the specific conditions, see our guides on HFpEF symptoms in women, coronary microvascular disease treatment, severe fatigue and cardiac diagnosis, and the thyroid-heart connection after 40.

Frequently Asked Questions

If my thyroid and iron are normal, what cardiac conditions could still cause my fatigue?

Three diagnoses dominate the overlooked list. HFpEF, heart failure with preserved ejection fraction, presents with exertional fatigue before breathlessness in midlife women. Coronary microvascular dysfunction starves the heart of flow despite clean arteries. Autonomic dysregulation from estrogen decline raises resting heart rate and disrupts the body’s ability to compensate when you stand or exert. All three are female-predominant, tied to menopause physiology, and routinely missed when the workup stops at TSH and ferritin. The tests to find them exist. The decision to order them is what goes missing.

Can a normal echocardiogram rule out heart failure as a cause of my fatigue?

No. A resting echocardiogram measures the heart at rest, and HFpEF often reveals itself only under exertion. Filling pressures can be normal lying on a table and climb sharply when you climb stairs. Roughly a third of patients with confirmed HFpEF have a normal or borderline resting echo. Diagnosis often requires exercise echocardiography, diastolic stress testing, or invasive hemodynamic measurement. A normal resting study reassures, but it does not exclude. If your fatigue is exertional and your resting echo was clean, the correct next step is an exercise echo, not reassurance.

Why do doctors so often tell midlife women with fatigue that they are depressed?

Because depression is easy to name and requires no further testing. But depression is a diagnosis of exclusion, not a default. When fatigue is severe, exertional, and accompanied by reduced exercise tolerance, the cardiac differential must be cleared first. A woman who could climb two flights last year and now stops halfway is describing a physiological change, not a mood. The clinical error is treating the mood and never asking why the stairs got harder. Her own conviction that something is wrong with her heart is clinical data worth acting on.

What single test best distinguishes cardiac fatigue from hormonal fatigue?

No single test does it alone, but NT-proBNP is the highest-yield first move. An elevated value points toward cardiac filling pressure and warrants imaging. The critical caveat: NT-proBNP runs falsely low in women with central abdominal weight, so a normal value in an overweight woman does not clear the heart. Pair it with an exercise echocardiogram or coronary flow reserve study when symptoms are exertional and standard labs are clean. The combination of an exertional symptom history and these targeted tests separates cardiac fatigue from hormonal fatigue far better than any lab in isolation.

When should I push for a cardiac evaluation after a normal standard workup?

Push when your fatigue is exertional rather than constant, when your exercise tolerance has measurably dropped over months, when you experience breathlessness or chest pressure with activity that resolves with rest, or when you have hypertension, central weight gain, or atrial fibrillation alongside the fatigue. These features shift the probability toward HFpEF or microvascular disease. A normal TSH and ferritin do not address any of them. Request NT-proBNP and an exercise echocardiogram. If your physician resists, the perimenopause cardiac risk assessment gives you a documented basis to ask again.